References
- Goldhirisch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 1997;6:89-97
- Kamby K, Senegelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer: a prospective study with more than 10 years of follow-up. Breast Cancer Res Treat 1997;45:181-92 https://doi.org/10.1023/A:1005845100512
- Martin TJ, Moseley JM. Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer 2000;7:271-84 https://doi.org/10.1677/erc.0.0070271
- Maffioli L, Florimonte L, Pagani L, Butti I, Roca I. Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 2004;31(S1):S143-8 https://doi.org/10.1007/s00259-004-1537-6
- Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-44 https://doi.org/10.1200/JCO.1998.16.6.2038
- Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001;93:534-8 https://doi.org/10.1093/jnci/93.7.534
- Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942-53 https://doi.org/10.1200/JCO.2004.08.181
- Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006;36:73-92 https://doi.org/10.1053/j.semnuclmed.2005.09.002
- Aoki J, Inoue T, Tomiyoshi K, Shinozaki T, Watanabe H, Takagishi K, Endo K. Nuclear imaging of bone tumors: FDG-PET. Semin Musculoskelet Radiol 2001;5:183-7 https://doi.org/10.1055/s-2001-15678
- Malhotra P, Berman CG. Evaluation of bone metastases in lung cancer: Improved sensitivity and specificity of PET over bone scanning. Cancer Control 2002;9:259-60
-
Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body
$^{18}F$ -2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:325-8 https://doi.org/10.1007/s00432-002-0342-5 - Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005;35:135-42 https://doi.org/10.1053/j.semnuclmed.2004.11.005
-
Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Suzuki Y, Yasuda S, Shohtsu A. Whole body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with
$^{99m}$ Tc-MDP bone scintigraphy. Nucl Med Commun 2001;22:875-9 https://doi.org/10.1097/00006231-200108000-00005 - Townsend DW, Beyer T. A combined PET/CT scanner: The path to true image fusion. Br J Radiol 2002;75:S24-30 https://doi.org/10.1259/bjr.75.suppl_9.750024
- Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet oncol 2005;6:392-400 https://doi.org/10.1016/S1470-2045(05)70206-0
- Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:1358-65
- Parfitt AM. Bone remodeling, normal and abnormal: A biological basis for the understanding of cancer-related bone disease and its treatment. Can J Oncol 1995;5(S1):1-10
- Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem 1999;45:1353-8
- Morgan-Parkes JH. Metastases: mechanism, pathways, and cases. AJR 1995;164:1075-82 https://doi.org/10.2214/ajr.164.5.7717206
- O'Sullivan JM, Cook GJR. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002;46: 152-9
- Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-40 https://doi.org/10.1038/bjc.1998.52
- Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol 1991;18:11-5
- Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: Clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000;59:271-8 https://doi.org/10.1023/A:1006308619659
- Hortobagyi GN. Unmet needs in metastatic bone disease and its complications: Is progress possible? Semin Oncol 2001;28:1-3 https://doi.org/10.1053/sonc.2001.22541
- Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer 2003;97:848-53 https://doi.org/10.1002/cncr.11123
- Libshitz HI, Hortobagyi GN. Radiographic evaluation of therapeutic response in bony metastases of breast cancer. Skeletal Radiol 1981;7:159-5 https://doi.org/10.1007/BF00361858
- Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology 2000;58:185-90 https://doi.org/10.1159/000012098
- Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 2002;29: 134-44 https://doi.org/10.1053/sonc.2002.34066
- Rubens RD. Bone metastases-the clinical problem. Eur J Cancer 1998;34:210-3 https://doi.org/10.1016/S0959-8049(97)10128-9
- Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001;9:3562-71
- Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo- controlled trial: Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54 https://doi.org/10.1200/JCO.1999.17.3.846
- Coleman RE. Management of bone metastases. Oncologist 2000;5:463-70 https://doi.org/10.1634/theoncologist.5-6-463
- LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol 2001;28:22-27
- Janjan N. Bone metastases: Approaches to management. Semin Oncol 2001;28:28-34
- Goris ML, Bretille J. Skeletal scintigraphy for the diagnosis of malignant metastatic disease to the bones. Radiother Oncol 1985;3:319-29 https://doi.org/10.1016/S0167-8140(85)80045-1
- Galasko CS, Doyle FH. The response to therapy of skeletal metastases from mammary cancer: Assessment by scintigraphy. Br J Surg 1972;59:85-8 https://doi.org/10.1002/bjs.1800590202
- Tryciecky EW, Gottschalk A, Ludema K. Oncologic imaging: Interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med 1997;27:142-51 https://doi.org/10.1016/S0001-2998(97)80044-X
- Coleman RE: Monitoring of bone metastases. Eur J Cancer 1998; 34:252-9 https://doi.org/10.1016/S0959-8049(97)10134-4
- Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000;88:2927-33 https://doi.org/10.1002/1097-0142(20000615)88:12+<2927::AID-CNCR8>3.0.CO;2-V
- Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 200145:53-64
- Galasko CS. Skeletal metastases and mammary cancer. Ann R Coll Surg Engl 1972;50:3-28
- Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996;22: 289-331 https://doi.org/10.1016/S0305-7372(96)90021-3
- Edelstyn GA, Gillespie PJ, Grebbell FS: The radiological demonstration of osseous metastases: Experimental observations. Clin Radiol 1967;18:158-62 https://doi.org/10.1016/S0009-9260(67)80010-2
- Ahn BC. Radiopharmaceuticals for the therapy of metastatic bone pain. Korean J of Nuclear Medicine and Molecular imaging 2006; 40:82-9
- Hortobagyi GN, Libshitz HI, Seabold JE. Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy. Cancer 1984;53:577-82 https://doi.org/10.1002/1097-0142(19840201)53:3<577::AID-CNCR2820530335>3.0.CO;2-U
- Corcoran RJ, Thrall JH, Kyle RW, Kaminski RJ, Johnson MC. Solitary abnormalities in bone scans of patients with extraosseous malignancies. Radiology 1976;121:663-7 https://doi.org/10.1148/121.3.663
- Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone 1991;12:S9-10 https://doi.org/10.1016/8756-3282(91)90059-R
- Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer 1997;80:1595-607 https://doi.org/10.1002/(SICI)1097-0142(19971015)80:8+<1595::AID-CNCR10>3.0.CO;2-V
- Galasko CS, Doyle FH. The detection of skeletal metastases from mammary cancer: A regional comparison between radiology and scintigraphy. Clin Radiol 1972;23:295-7 https://doi.org/10.1016/S0009-9260(72)80051-5
- Lee YT. Bone scanning in patients with early breast carcinoma: Should it be a routine staging procedure? Cancer 1981;47:486-95 https://doi.org/10.1002/1097-0142(19810201)47:3<486::AID-CNCR2820470311>3.0.CO;2-U
- Coleman RE, Rubens RD, Fogelman I. Reappraisal of the baseline bone scan in breast cancer. J Nucl Med 1988;29:1045-9
- Dershaw DD, Osborne M. Imaging techniques in breast cancer. Semin Surg Oncol 1989;5:82-93 https://doi.org/10.1002/ssu.2980050204
- Loeffler RK, DiSimone RN, Howland WJ. Limitations of bone scanning in clinical oncology. JAMA 1975;234:1228-32 https://doi.org/10.1001/jama.234.12.1228
- Theriault RL, Hortobagyi GN. Bone metastasis in breast cancer. Anticancer Drugs 1992;3:455-62 https://doi.org/10.1097/00001813-199210000-00002
- Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer. Clin Positron Imaging 2000;3:45-9 https://doi.org/10.1016/S1095-0397(00)00042-X
- O'Mara R. Skeletal scanning in neoplastic disease. Cancer 1976;37:480-6 https://doi.org/10.1002/1097-0142(197601)37:1+<480::AID-CNCR2820370713>3.0.CO;2-2
-
Horiuchi-Suzuki K, Saji H, Ohta H: What is the source of the skeletal affinity of
$^{99m}TC$ -V-DMSA? Eur J Nucl Med Mol Imaging 2004;31:1675-6 https://doi.org/10.1007/s00259-004-1651-5 - Jocobson AF. (1996) Bone scanning in metastatic disease. In: Collier BD Jr, Fogelman I, Rosenthall L (eds) skeletal nuclear medicine. Mosby, St. Louis, pp 87.123
- Resnick D (1996) Skeletal metastases. In: Resnick D (ed) Bone and joint imaging. W.B. Saunders, Philadelphia, pp 1076.1091
- Kosuda S, Kaji T, Yokoyama H, Yokokawa T, Katayama M, Iriye T, Uematsu M, Kusano S. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? J Nucl Med 1996;37:975-8
- Roland J, van den Weyngaert D, Krug B, Brans B, Scalliet P, Vandevivere J. Metastases seen on SPECT imaging despite a normal planar bone scan. Clin Nucl Med 1995;20:1052-4 https://doi.org/10.1097/00003072-199512000-00002
- Sedonja I, Budihna NV. The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine. Clin Nucl Med 1999;24:407-13 https://doi.org/10.1097/00003072-199906000-00006
- Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT. Diagnostic bone scanning in oncology. Semin Nucl Med 1997;27:107-41 https://doi.org/10.1016/S0001-2998(97)80043-8
- Cook GJ, Fogelman I. Skeletal metastases from breast cancer: Imaging with nuclear medicine. Semin Nucl Med 1999;29:69-79 https://doi.org/10.1016/S0001-2998(99)80031-2
- Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9 https://doi.org/10.1200/JCO.1998.16.10.3375
- Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases. Semin Oncol 2001;28:11-6 https://doi.org/10.1053/sonc.2001.24369
- Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, Kotzerke J, Guhlmann A, Delling G, Reske SN. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40:1637-43
- Franzius C, Bielack S, Flege S, Sciuk J, Jurgens H, Schober O. Prognostic significance of 18F-FDG and 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002;43: 1012-7
- Gulenchyn KY, Papoff W. Technetium-99m MDP scintigraphy: an insensitive tool for the detection of bone marrow metastases. Clin Nucl Med 1987;12:45-6 https://doi.org/10.1097/00003072-198701000-00011
-
Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN.
$^{18}F$ -Fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatousbone marrow. J Clin Oncol 1998;16:603-9 https://doi.org/10.1200/JCO.1998.16.2.603 -
Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E. Assessment of malignant skeletal disease: Initial experience with
$^{18}F$ -fluoride PET/CT and Comparison between$^{18}F$ -fluoride PET and$^{18}F$ -fluoride PET/CT. J Nucl Med 2004;45:272-8 -
Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance?
$^{18}F$ -FDG and CT contrast agents in dual-modality$^{18}F$ -FDG PET/CT. J Nucl Med 2004;45(S1):S56-65 - Kamel EM, Burger C, Buck A, von Schulthess GK, Goerres GW. Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol 2003;13: 724-8 https://doi.org/10.1007/s00330-002-1564-2
- Bockisch A, Beyer T, Antoch G, Freudenberg LS, Kuhl H, Debatin JF, Muller SP. Positron emission tomography/computed tomographyimaging protocols, artifacts, and pitfalls. Mol Imaging Biol 2004; 6:188-99 https://doi.org/10.1016/j.mibio.2004.04.006
- Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005;35: 135-42 https://doi.org/10.1053/j.semnuclmed.2004.11.005
- Cherry SR. The 2006 Henry N. Wagner Lecture: Of mice and men (and positrons)-advances in PET imaging technology. J Nucl Med 2006;47:1735-45
- Fanti S, Franchi R, Battista G, Monetti N, Canini R. PET and PET-CT. State of the art and future prospects. Radiol Med 2005;110:1-15